Steatosis
12
1
1
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
2 terminated out of 12 trials
66.7%
-19.8% vs benchmark
17%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
Clinical Validation of a Raman Spectroscope to Determine Hepatic Fat Content
HIBOC = Hepatic Imaging Biomarkers in Obese Children
Reversal of Right Ventricular Steatosis in Pulmonary Hypertension
Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
Evaluation of the Diagnostic of Hepatic Fibrosis With the in Severe Obese Patients Candidates to Bariatric Surgery
Effects of Fat and Carbohydrates in Obese Men
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
Fatty Acids, Genes and Microbiota in Fatty Liver
Very Low Calorie Liquid Diet for Pre op Patients
Identification of Protective and Worsening Steatohepatitis (NASH) Factors